|
|
Please type responses here: |
|
First Name:
|
|
|
Last Name:
|
|
|
Email Address:
|
|
|
Retype Email Address:
|
|
|
Title:
|
|
|
Institution:
|
|
|
Phone Number:
|
|
|
City:
|
|
|
State/Province:
|
|
|
Postal/Zip Code:
|
|
|
Country:
|
|
|
What topics would you like to see covered in future POC Group Webinars?
|
|
|
Overall, how would you rate your satisfaction with this Point of Care Web Meeting?
|
Extremely satisfied
Very satisfied
Somewhat satisfied
Dissatisfied
|
|
Your feedback helps your webinar producers and sponsors improve the overall quality of their products and services.
|
|
I would like to know more about (choose all that apply):
|
Adding a device type to RALS
Knowing more about operator management tools
Scalable feature sets
The Configurable Device Driver tool
|
|
What current data management system(s) are you using? Choose all that apply:
|
Abbott PrecisionWeb™
GEMweb® Plus
Orchard® Point-of-Care
Radiometer AQURE
Radiometer Radiance
RALS™ Connectivity System
Roche cobas® IT 1000 / cobas® infinity POC
SIEMENS POCcelerator™
SIEMENS RapidComm®
SIEMENS UniPOC™
Telcor QML®
None
Other
|
|
If you chose ‘other’ in the question above, please list your current data management system(s):
|
|
|
Do you currently use Cepheid tests?
|
Yes
No
|
|
Are you looking to add any new CLIA waived molecular tests this year?
|
Yes
No
|
|
Would you like to be contacted to learn more about Cepheid's POC solutions?
|
Yes
No
|
|
Which of the following point of care SARS-CoV-2 diagnostic test methods are being used in your outpatient settings? Please select all that apply:
|
PCR
Other molecular method (e.g. isothermal NAAT)
Visually read lateral flow immunoassay
Lateral flow immunoassay with a reader
Microfluidic fluorescent immunoassay
Other
N/A
|
|
Are you open to learning more about how the LumiraDx Platform and microfluidic test technology might fit into your decentralized lab settings?
|
Yes
No
N/A
|
|
What type of point of care tests do you currently utilize? Please check all that apply:
|
Diabetes monitoring (HbA1c)
Lipid Panel
COVID-19
Flu
Strep
Drugs of Abuse
Other
I do not do point of care testing
|
|
Would you like to know more about Abbott’s HbA1c and cholesterol point of care testing offerings?
|
Yes – Both HbA1c and Cholesterol Testing
Yes- HbA1c only
Yes- Cholesterol only
No
Not Sure
|
|
Would you be interested in learning how the CLIA-waived CBC can help reduce lab send outs?
|
Yes
No
|
|
Will you be adding CLIA-waived tests to your practices within next 6 months?
|
Yes
No
|
|
Would you like to receive ASCLS PACE credit for this session, program number 174-005-24? (If no, you do not need to complete the following questions.)
|
Yes
No
|
|
To receive ASCLS PACE credit (PACE Program number 174-005-24, California Agency #0001) for "Point of Care Testing: Cost vs. Convenience" presented on April 11, 2024, you will be required to complete the following program evaluation.
|
|
If the following is true, please answer "Yes": I have attended the full instructional time for this program. I understand that completion of the program is necessary to receive the contact hours awarded for the program.
|
Yes
No
|
|
SPEAKER RATING
|
|
To what extent was the speaker knowledgeable, organized and effective during the presentation? (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
To what extent did the speaker clarify and focus on the stated objectives? (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
To what extent were the speaker's teaching methods & aids appropriate & effective? (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
OBJECTIVES RATING:
To what extent was each objective achieved?
|
|
Describe the one clear clinical reason to perform lab tests at POCT. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Identify how lab testing impacts health screening, management of peri-acute conditions, and chronic disease management. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Discuss more about the relationship between MACRA and in office lab testing. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Explain information on lab testing and morbidity/mortality for the 10 leading causes of death in the US. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Assess how utilization management influences test selection. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
PROGRAM CONTENT RATING
|
|
To what extent did the program content relate to the program's objectives? (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Rate the contribution of this session to your overall knowledge of this subject. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Rate your overall degree of satisfaction with this session. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Comments:
|
|
|
Thank you for attending this PACE approved program and completing this evaluation. Questions? Call Whitehat Communications at 434 202 8365.
|
|
|
